Use access key #2 to skip to page content.
$3.17 -0.23 (-6.76%)
7/23/2008 11:23 AM

GPC Biotech AG (ADR) (GPCB)

CAPS Rating:
*

The Company is publicly traded biopharmaceutical company focused on discovering, developing and commercializing new anticancer drugs.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating GPCB

Add Stock to Watchlist

What the Community Thinks

Total Members

59 Outperforms
80 Underperforms
 

All-Stars

14 Outperforms
43 Underperforms
 

Wall Street

0 Outperforms
2 Underperforms
 

Members bullish on GPCB are also bullish on:

Members bearish on GPCB are also bearish on:

Ticker Tags

Micro Cap (4824), Munich (5), Biotechnology (294), Germany (21)
Suggest a tag

GPC Biotech AG (ADR) At A Glance

Current Price: $3.17
Last Trade Time: 7/23/2008 11:23 AM
Open: $3.25
Previous Close: $3.40
Daily Range: $3.15 - $3.25
52-Week Range: $2.23 - $15.20
Volume: 1,900
Market Cap: $125.25M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

GPCB VS S&P 500 (SPY)

GPCB 12 month chart vs. S&P

News & Discussion Boards

Sorry no news articles available for GPCB.

Top Bull Pitch

Recs

2

GPC Biotech AG (ADR) (GPCB)

Avatar tr4sh80 (< 20) Submitted: 7/31/07 5:40 PM

Looks like they've got a great new cancer treatment ready to go. Was smart of them to withdraw accelerated request for FDA approval pending more result information. Better safe than sorry, and it will give them time to build a better case for FDA approval. Expect big gains in the short and maybe eve...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

GPC Biotech AG (ADR) (GPCB)

Avatar fOOLSONPARADE (98.92) Submitted: 3/02/07 11:19 PM

I seem to be good a buying stocks when they begin to fall so I now have used my "ability" for shorting sotcks. So far it has paid off in my real portfolio. Here is one more that looks like the only elevator button that works is DOWN.

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 12 :   1 2 3 Next »

Recs

0

 (GPCB)

Avatar JonAtkins57 (26.74) Submitted: 6/30/08 1:50 PM : Underperform Start Price: $3.78 GPCB Score: 16.29

Market Cap > 100M and < 1B
Gross Margin % < -10
Net Profit Margin % < -10
EPS < -1

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GPCB)

Avatar smith45416 (< 20) Submitted: 6/13/08 8:46 PM : Outperform Start Price: $4.21 GPCB Score: -20.03

How many times can you go wrong with a biopharmceutical company

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GPCB)

Avatar Dublin063 (22.06) Submitted: 5/30/08 1:41 PM : Underperform Start Price: $3.90 GPCB Score: 10.05

The Company is publicly traded biopharmaceutical company focused on discovering, developing and commercializing new anticancer drugs.





Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GPCB)

Avatar lavongduhr (< 20) Submitted: 5/30/08 9:41 AM : Outperform Start Price: $4.10 GPCB Score: -14.08

biopharmaceutical company that researches and develops anitcancer drugs. currently in phase I trial for satraplatin, which is a radiation drug that is a therapeutic for non-small lung cancer patients

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GPCB)

Avatar handoverhill (< 20) Submitted: 5/14/08 7:22 AM : Outperform Start Price: $4.15 GPCB Score: -14.51

This stock is in the healthcare sector of the market and the industry of biotechnology and drugs. The charts show us again that this stock is being underrated.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 12 :   1 2 3 Next »

Wall Street

Results 1 - 2 of 2  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackPiperJaff 78.77 11/02/07 Underperform NS $4.40-27.95%-15.39%+12.56
TrackDeutscheSec 89.63 10/31/07 Underperform NS $4.25-25.41%-16.74%+8.68

Results 1 - 2 of 2  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners